BIONEUTRA ANNOUNCES FINANCIAL RESULTS FOR TEN-MONTH PERIOD ENDED DECEMBER 31, 2015

EDMONTON, Alberta, April 30, 2015 – BioNeutra Global Corporation (CSE: BGA) (“BioNeutra” or the “Company“) is pleased to announce today its audited financial results for the ten-month period ended December 31, 2014. BioNeutra is a functional and health food ingredient manufacturer that uses its patented process to produce isomalto-oligosaccharide (“IMO”) which it sells under its trademark VitaFiber™.


Highlights for the Ten-Month Period Ended December 31, 2014


• In the ten-month period ended December 31, 2014, BioNeutra reported revenues of $13,060,336, a 72% increase over revenues of $7,577,334 for the twelve-month period ended February 28, 2014. The Company’s increased revenues were driven by growing sales of VitaFiber™ to food manufacturers targeting functional and health food markets.


• The Company’s gross margin percentage for the ten-month period ended December 31, 2014 was 45%, contributing to a net income of $4,258,670, or $0.18 per share. This compares with a net income of $678,856 for the twelve-month period ended February 28, 2014.


• At December 31, 2014, the Company had a cash balance of $2,084,687 and working capital of $3,976,934, as compared with $1,190,600 and $350,477 at February 28, 2014. The Company also has access to a $500,000 credit facility to assist with working capital needs; however, the Company had not drawn on this credit facility as of December 31, 2014.


• On November 4, 2014, BioNeutra was listed on the Canadian Securities Exchange (“CSE”) under the symbol “BGA”. The CSE listing was the concluding step of a transaction whereby BioNeutra North America Inc. and BioNeutra International Limited became subsidiaries of the Company.


• On November 25, 2014, BioNeutra North America Inc. was awarded the BioAlberta “Company of the Year Award” at the 15th Annual BioAlberta AGM and Awards Gala. This award was presented to BioNeutra North America Inc. for its significant achievement within the marketplace and Alberta’s business community through strong performance and a leadership role. See www.bioalberta.com/bioneutra-north-america-inc.


• In Q4 2014, BioNeutra began to sell VitaFiber™ to manufacturers and consumers in Europe and the United Kingdom and supported its European distribution by establishing a warehouse facility in Amsterdam.


Subsequent Events


• On January 5, 2015, BioNeutra North America Inc. was listed on the Alberta Venture Fast 50, a program that recognizes Alberta businesses with significant growth in revenue, assets, capital expenditures and employees over a three-year period.

See www.albertaventure.com/2015/01/fg50-albertas-2015-fast-growth-50-list/.


• In March 2015, BioNeutra North America Inc. reached an agreement with prominent global online retailer Amazon.com to sell VitaFiber™ through its online store.


• On April 23, 2015, BioNeutra North America Inc. entered into an agreement to acquire a mixed-use manufacturing and office building of approximately 47,000 square feet situated on 2.65 acres of land in a light industrial area of Edmonton, Alberta. The Company intends to use this property for its head office, to establish Canadian manufacturing capacity, and to expand its research and development capabilities. The Company expects to complete the purchase of this property in Q3 2015 and begin renovations shortly thereafter.


Financial Summary for the Ten-Month Period Ended December 31, 2014

Revenue


Ten Months Ended December 31, 2014 Sales Revenue: $13,060,336

Year Ended February 28, 2014 Sales Revenue: $7,577,334

Increase Sales Revenue ($): $5,483,002

Increase Sales Revenue (%): 72%


Total sales for the ten-month period ended December 31, 2014 were $13,060,336, a 72% increase over sales of $7,577,334 for the twelve-month period ended February 28, 2014. This increase in revenue was a result of growing sales of VitaFiber™ to major functional and health food manufacturers who in turn experienced significant growth in their own global sales.


Gross Profit

The Company’s gross profit for the ten-month period ended December 31, 2014 was $5,891,181 on gross margins of 45%. This represents an increase of $2,314,292 from gross profit of $3,576,889 for the twelve-month period ended February 28, 2014.


Net Income

Ten Months Ended December 31, 2014 Net Income: $4,258,670

Year Ended February 28, 2014 Net Income: $678,856

Increase Net Income ($): $3,579,814

Increase Net Income(%): 527%


Increased sales combined with a steady gross margin percentage resulted in net income of $4,258,670 or $0.18 per share for the ten-month period ended December 31, 2014. This represents a greater than five-fold increase from net income of $678,856 for the twelve-month period ended February 28, 2014.


Financial Condition & Liquidity


At December 31, 2014, the Company had a cash balance of $2,084,687 and working capital of $3,976,934, as compared with $1,190,600 and $350,477 at February 28, 2014. The Company also has access to a $500,000 credit facility to assist with working capital needs; however, the Company had not drawn on this credit facility as of December 31, 2014.


Income Tax Recovery


As at December 31, 2014, the Company had Canadian tax losses with a tax benefit of $1,574,015. These losses may be carried forward and expire beginning in 2030. Deferred income tax assets have been recognized from the amalgamation of the Company’s subsidiaries which has provided loss carryforwards that the Company may use to offset taxable income in the future.



  • Facebook
  • Twitter
  • LinkedIn

9608 25 Avenue NW

Edmonton, Alberta T6N 1J4

Canada

Tel: 1.780.466.1481

Fax: 1.780.801.0036

Business Hours

Monday to Friday

8:30 AM - 4:30 PM

ⓒ 2020 BioNeutra